Avacta Group (LON:AVCT) Share Price Passes Above 200 Day Moving Average – Should You Sell?

Avacta Group Plc (LON:AVCT) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 68.76 and traded as high as GBX 70. Avacta Group shares last traded at GBX 68, with a volume of 672,838 shares traded.

Avacta Group Stock Down 1.2%

The business’s 50-day moving average is GBX 70.94 and its two-hundred day moving average is GBX 68.94. The firm has a market capitalization of £317.18 million, a price-to-earnings ratio of -7.01 and a beta of 1.12. The company has a debt-to-equity ratio of 602.46, a quick ratio of 4.96 and a current ratio of 0.89.

Avacta Group (LON:AVCT) last issued its earnings results on Tuesday, May 19th. The biotechnology company reported GBX (9.27) EPS for the quarter. The firm had revenue of GBX 11 million during the quarter. Avacta Group had a negative net margin of 33,961.06% and a negative return on equity of 2,929.47%. On average, equities analysts anticipate that Avacta Group Plc will post -9.9011833 earnings per share for the current year.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).